Revise to specify that 66% of cases lacked initial clinical suspicion for nodular fasciitis.
Background
Nodular fasciitis is a benign soft-tissue lesion that can mimic more aggressive tumors, leading to potential misdiagnosis. Accurate identification of nodular fasciitis is crucial for appropriate management and to avoid unnecessary interventions. The integration of molecular testing into the diagnostic process can improve confidence in challenging cases where clinical and histological features are ambiguous.
Data Highlights
Testing Method
Detection Rate
Fluorescence in situ hybridization
83% (15 of 18 cases)
Next-generation sequencing
Confirmed rearrangements in all inconclusive cases
Key Findings
Molecular testing identified USP6 rearrangements in all non-specific cases of nodular fasciitis.
66% of cases did not initially raise clinical suspicion for nodular fasciitis.
Five cases occurred in atypical locations, presenting with pain or neurologic deficits.
Next-generation sequencing revealed rare fusion partners in some cases, with younger patients presenting atypical fusions.
Histologic features were consistent with nodular fasciitis across all cases.
Clinical Implications
The findings emphasize the necessity of molecular diagnostics in evaluating soft-tissue lesions with non-specific features. Clinicians should consider molecular testing to enhance diagnostic accuracy and guide management in ambiguous cases of nodular fasciitis.
Conclusion
Molecular testing plays a critical role in the accurate diagnosis of nodular fasciitis, particularly in cases with atypical presentations. This approach may improve diagnostic confidence and patient management.
Genetically predicted urinary metabolite levels were associated with schizophrenia, bipolar disorder, attention-deficit/hyperactivity disorder, and anorexia nervosa in a Mendelian randomization analysis.
